Characterisation of pore structures of pharmaceutical tablets: A review

Tutkimustuotos: Lehtiartikkelivertaisarvioitu

Tutkijat

  • Daniel Markl
  • Alexa Strobel
  • Rüdiger Schlossnikl
  • Johan Bøtker
  • Prince Bawuah
  • Cathy Ridgway
  • Jukka Rantanen
  • Thomas Rades
  • Patrick Gane

  • Kai Erik Peiponen
  • J. Axel Zeitler

Organisaatiot

  • University of Cambridge
  • University of Copenhagen
  • University of Eastern Finland
  • Omya International AG

Kuvaus

Traditionally, the development of a new solid dosage form is formulation-driven and less focus is put on the design of a specific microstructure for the drug delivery system. However, the compaction process particularly impacts the microstructure, or more precisely, the pore architecture in a pharmaceutical tablet. Besides the formulation, the pore structure is a major contributor to the overall performance of oral solid dosage forms as it directly affects the liquid uptake rate, which is the very first step of the dissolution process. In future, additive manufacturing is a potential game changer to design the inner structures and realise a tailor-made pore structure. In pharmaceutical development the pore structure is most commonly only described by the total porosity of the tablet matrix. Yet it is of great importance to consider other parameters to fully resolve the interplay between microstructure and dosage form performance. Specifically, tortuosity, connectivity, as well as pore shape, size and orientation all impact the flow paths and play an important role in describing the fluid flow in a pharmaceutical tablet. This review presents the key properties of the pore structures in solid dosage forms and it discusses how to measure these properties. In particular, the principles, advantages and limitations of helium pycnometry, mercury porosimetry, terahertz time-domain spectroscopy, nuclear magnetic resonance and X-ray computed microtomography are discussed.

Yksityiskohdat

AlkuperäiskieliEnglanti
Sivut188-214
Sivumäärä27
JulkaisuInternational Journal of Pharmaceutics
Vuosikerta538
Numero1-2
TilaJulkaistu - 1 maaliskuuta 2018
OKM-julkaisutyyppiA2 Arvio tiedejulkaisuussa (artikkeli)

ID: 17418344